Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corsodyl Original Dentifrice is a specialized therapeutic toothpaste developed by Haleon (formerly GSK Consumer Healthcare), containing a high concentration of 67% w/w sodium bicarbonate and 0.31% w/w sodium fluoride (providing 1400 ppm fluoride). It is specifically formulated for the management of gingivitis and the reduction of dental plaque accumulation. The mechanism of action involves the physical disruption of the dental plaque biofilm by sodium bicarbonate particles, which facilitates plaque removal during brushing and neutralizes acidic metabolic byproducts of oral bacteria. The sodium fluoride component promotes the remineralization of tooth enamel and provides protection against dental caries. Clinically, it is used to reduce gingival inflammation and bleeding, which are hallmark symptoms of gum disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Corsodyl Original Dentifrice.